Biogennix Receives FDA Clearance for Expanded Use of Agilon Moldable and Morpheus Moldable Products
Irvine-based Biogennix , LLC an osteobiologics company specializing in bone graft products for fusion procedures, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication for its Agilon Moldable and Morpheus Moldable bone grafting products.
- Irvine-based Biogennix , LLC an osteobiologics company specializing in bone graft products for fusion procedures, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication for its Agilon Moldable and Morpheus Moldable bone grafting products.
- Agilon Moldable is unique among moldable synthetic bone grafts, as it contains both collagen with an organic polymer carrier and Biogennix’s proprietary TrelCor granules.
- "Receiving expanded indications for our flagship Agilon Moldable and Morpheus products is exciting news," said Chris MacDuff, Biogennix’s CEO.
- Based on enthusiastic feedback from over 75,000 successful cases to date, we anticipate increased market adoption this year for both Agilon and Morpheus moldable products."